Oxazolidinone antibacterials:

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |

Oxazolidinone derivatives as antimicrobials **US patent 6,734,307** (issued May, 2004,assigned to Ranbaxy) ;

Oxazolidinone piperazinyl derivatives as potential antimicrobials,US **patent 6,956,040** (issued October 2005, ,assigned to Ranbaxy) ;

[Synthesis and Biological activity of Novel Oxazolidinones, Bioorg Med Chem Lett. 2009, 15.](https://sitebuilder.intuitwebsites.com/~site/builder/stage.jsp?pageId=x52656c6576616e742d5075626c69636174696f6e732e787066)

​

[Synthesis and antimicrobial activity of potent heterticyclic oxazolidinones and the identification of RBX 7800, Bioorg Med Chem Lett. 2007, 17, 6714-19.](https://sitebuilder.intuitwebsites.com/~site/builder/stage.jsp?pageId=x52656c6576616e742d5075626c69636174696f6e732e787066)

Several potent oxazolidinone antibacterial agents were obtained by systematic modification of the linker between the five-membered heterocycle and the piperazinyl ring of RBx 7644 (Ranbezolid, I) and its thienyl analog, leading to the identification of an expanded spectrum compd. RBx 8700 (II).



[Synthesis and antimicrobial activity of novel Thiazolidinones, ARKIVOC, 2005 ( ii) , 46-5](https://sitebuilder.intuitwebsites.com/~site/builder/stage.jsp?pageId=x52656c6576616e742d5075626c69636174696f6e732e787066).

​

A novel and efficient synthesis of 4-substituted 2-oxazolidinones, e.g., I, is described. As key steps, Sharpless asym. dihydroxylation (AD) of appropriately substituted O-allylcarbamates and intramol. cyclization were utilized.



|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |